Erlotinib Completed Phase 2 Trials for Leukemia, Myelomonocytic, Acute Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01174043Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia